Key Takeaways
- Analyst Raghuram Selvaraju set a price target of US$6.00 for Aardvark Therapeutics after a full FDA clinical hold on its drug ARD-101.
- Preliminary clinical data unblinding will guide decisions on the development of ARD-101, potentially extending the timeline by 18 to 24 months.
- Aardvark ended Q1 2026 with US$91.2 million cash reserves but projected significant losses with no revenue expected in the immediate future.
FDA Clinical Hold on ARD-101
On July 20, 2026, H.C. Wainwright analyst Raghuram Selvaraju reaffirmed a Neutral rating for Aardvark Therapeutics Inc. (AARD:NASDAQ), establishing a price target of US$6.00 per share. This target signals a 2% potential upside from the company’s recent closing price of US$5.86. This outlook follows a full U.S. Food and Drug Administration (FDA) clinical hold on Aardvark’s lead asset, ARD-101, linked to a prior voluntary development pause.
The FDA’s hold impacts all clinical studies under the Investigational New Drug (IND) application, including the Phase 3 HERO trial evaluating ARD-101’s efficacy for hyperphagia in patients with Prader-Willi Syndrome (PWS). The company is currently engaged with the FDA to resolve the hold and aims to unblind existing clinical data from the HERO and accompanying open-label extension (OLE) study to assess overall efficacy and safety.
Impact on Development Timeline
The implications of the FDA’s hold are uncertain, but Selvaraju speculated that the HERO trial might need a full repeat, despite its 12-week evaluation period. Should the hold be lifted later in the year, it could still delay ARD-101’s development by approximately 18 to 24 months. No initial dosing has occurred in studies of the fixed-dose combination candidate ARD-201, which includes ARD-101, leaving its future unclear while the hold remains in effect.
Financial Overview
As of Q1 2026, Aardvark reported cash reserves of US$91.2 million, with management projecting these funds will support operations through mid-2027. The company recorded a net loss of US$21.6 million for the quarter, translating to US$0.99 per share. Predictions suggest a net loss of US$83.1 million (US$3.80 per share) for the full year 2026, narrowing to US$51.2 million (US$1.98 per share) in 2027, with no revenues anticipated.
Valuation and Associated Risks
The price target relies on discounted cash flow analysis, incorporating a 12% discount rate and a 2% terminal growth rate. Downward revisions in approval probabilities yield an enterprise value of around US$168 million. Risks include the possibility of the clinical hold remaining, poor Phase 3 HERO trial results, and challenges in securing regulatory approval or positive trial outcomes.
As of July 17, 2026, Aardvark shares traded at US$5.86, with the price target suggesting a small potential return. The report also noted Rhythm Pharmaceuticals, which has a Buy rating and a price target of US$105.00.
The content above is a summary. For more details, see the source article.